Uso combinado de modelos de estresse no trabalho e a saúde auto-referida na enfermagem

OBJETIVO: Identificar combinações de dois modelos do estresse psicossocial do trabalho em equipes de enfermagem e sua associação com a saúde auto-referida. MÉTODOS: Estudo transversal com trabalhadoras de três hospitais públicos do Município do Rio de Janeiro, RJ (N=1307). Foi aplicado questionário multidimensional que incluiu duas escalas de estresse no trabalho (modelo demanda-controle e desequilíbrio esforço-recompensa) em 2006. Foram considerados o modelo demanda e controle parcial e completo (inclui apoio social no trabalho), assim como o esforço e recompensa parcial e completo (inclui excesso de comprometimento com o trabalho). Modelos de regressão múltipla foram utilizados para estimar razões de chances ajustadas e seus respectivos intervalos com 95% de confiança. RESULTADOS: As dimensões de ambos os modelos estiveram independentemente associadas à situação de saúde, com odds ratios entre 1,70 e 3,37. O modelo parcial demanda-controle mostrou-se menos associado à saúde (OR = 1,79; IC95% 1,26;2,53) quando comparado ao de desequilíbrio esforço-recompensa (OR=2,27; IC95% 1,57;3,30). A incorporação do apoio social e do excesso de comprometimento com o trabalho aumentou a força de associação dos modelos demanda-controle e desequilíbrio esforço-recompensa, respectivamente. Foi observado aumento na força de associação quando os dois modelos parciais foram combinados. CONCLUSÕES: Os resultados indicam melhor desempenho do modelo desequilíbrio esforço-recompensa para este grupo específico e para o desfecho avaliado e vantagem do uso de modelos completos ou do uso combinado em modelos parciais.OBJETIVO: Identificar combinaciones de dos modelos de estrés psicossocial del trabajo en equipos de enfermería y su asociación con la salud auto referida. MÉTODOS: Estudio transversal con trabajadoras de tres hospitales públicos del Municipio de Rio de Janeiro, Sureste de Brasil, (N=1307). Se aplicó cuestionario multidimensional que incluyó dos escalas de estrés en el trabajo (modelo demanda-control y desequilibrio esfuerzo-recompensa) en 2006. Se consideraron el modelo demando y control parcial y completo (incluye apoyo social en el trabajo), así como el esfuerzo y recompensa parcial y completo (incluye exceso de compromiso con el trabajo). Se utilizaron modelos estadísticos múltiples para estimar razones de probabilidades ajustadas y sus respectivos intervalos con 95% de confianza. RESULTADOS: Las dimensiones de ambos modelos estuvieron independientemente asociadas con la salud autoreferida, con odds ratios entre 1,70 y 3,37. El modelo parcial demanda-control se mostró menos asociado a la salud (OR=1,79; IC 95% 1,26;2,53) al compararlo con el desequilibrio esfuerzo-recompensa (OR=2,27; IC 95% 1,57;3,30). La incorporación del apoyo social y del exceso de compromiso con el trabajo aumentó la fuerza de asociación de los modelos demanda-control y desequilibrio esfuerzo-recompensa, respectivamente. Se observó aumento en la fuerza de asociación al combinarse los dos modelos parciales. CONCLUSIONES: Los resultados indican mejor desempeño del modelo desequilibrio esfuerzo-recompensa para este grupo específico y para el resultado evaluado y ventaja en el uso de modelos completos o del uso combinado en modelos parciales.OBJECTIVE: To identify combinations of two models of psychosocial stress at work among nursing teams and their associations with self-rated health. METHODS: This was a cross-sectional study among workers at three public hospitals in the municipality of Rio de Janeiro, Southeastern Brazil (N = 1307). In 2006, a multidimensional questionnaire including two scales for measuring stress at work (demand-control and effort-reward imbalance models) was administered. Partial and complete (including social support at work) demand-control models were considered, along with partial and complete (including excessive commitment to work) effort-reward models. Multiple logistic regression models were used to estimate adjusted odds ratios and their respective 95% confidence intervals. RESULTS: The dimensions of both models were independently associated with self-rated health, with odds ratios between 1.70 and 3.37. The partial demand-control model was less associated with health (OR = 1.79; 95%CI 1.26;2.53) than was the partial effort-reward imbalance model (OR = 2.27; 95%CI 1.57;3.30). Incorporation of social support and excessive commitment to work increased the strength of the demand-control and effort-reward imbalance models, respectively. Increased strength of association was observed when the two partial models were combined. CONCLUSIONS: The results indicate that the effort-reward imbalance model performed better for this specific group and for the outcome evaluated, and that there was an advantage in using complete models or combinations of partial models

An investigation of the phase locking index for measuring of interdependency of cortical source signals recorded in the EEG

The phase locking index (PLI) was introduced to quantify in a statistical sense the phase synchronization of two signals. It has been commonly used to process biosignals. In this article, we investigate the PLI for measuring the interdependency of cortical source signals (CSSs) recorded in the Electroencephalogram (EEG). To this end, we consider simple analytical models for the mapping of simulated CSSs into the EEG. For these models, the PLI is investigated analytically and through numerical simulations. An evaluation is made of the sensitivity of the PLI to the amount of crosstalk between the sources through biological tissues of the head. It is found that the PLI is a useful interdependency measure for CSSs, especially when the amount of crosstalk is small. Another common interdependency measure is the coherence. A direct comparison of both measures has not been made in the literature so far. We assess the performance of the PLI and coherence for estimation and detection purposes based on, respectively, a normalized variance and a novel statistical measure termed contrast. Based on these performance measures, it is found that the PLI is similar or better than the CM in most cases. This result is also confirmed through analysis of EEGs recorded from epileptic patients

Metabolic phenotyping for discovery of urinary biomarkers of diet, xenobiotics and blood pressure in the INTERMAP Study: an overview

The etiopathogenesis of cardiovascular diseases (CVDs) is multifactorial. Adverse blood pressure (BP) is a major independent risk factor for epidemic CVD affecting ~40% of the adult population worldwide and resulting in significant morbidity and mortality. Metabolic phenotyping of biological fluids has proven its application in characterizing low-molecular-weight metabolites providing novel insights into gene-environmental-gut microbiome interaction in relation to a disease state. In this review, we synthesize key results from the INTERnational study of MAcro/micronutrients and blood Pressure (INTERMAP) Study, a cross-sectional epidemiologic study of 4680 men and women aged 40-59 years from Japan, the People's Republic of China, the United Kingdom and the United States. We describe the advancements we have made regarding the following: (1) analytical techniques for high-throughput metabolic phenotyping; (2) statistical analyses for biomarker identification; (3) discovery of unique food-specific biomarkers; and (4) application of metabolome-wide association studies to gain a better understanding into the molecular mechanisms of cross-cultural and regional BP differences

Model-Based Analysis and Optimization of the Mapping of Cortical Sources in the Spontaneous Scalp EEG

The mapping of brain sources into the scalp electroencephalogram (EEG) depends on volume conduction properties of the head and on an electrode montage involving a reference. Mathematically, this source mapping (SM) is fully determined by an observation function (OF) matrix. This paper analyses the OF-matrix for a generation model for the desynchronized spontaneous EEG. The model involves a four-shell spherical volume conductor containing dipolar sources that are mutually uncorrelated so as to reflect the desynchronized EEG. The reference is optimized in order to minimize the impact in the SM of the sources located distant from the electrodes. The resulting reference is called the localized reference (LR). The OF-matrix is analyzed in terms of the relative power contribution of the sources and the cross-channel correlation coefficient for five existing references as well as for the LR. It is found that the Hjorth Laplacian reference is a fair approximation of the LR, and thus is close to optimum for practical intents and purposes. The other references have a significantly poorer performance. Furthermore, the OF-matrix is analyzed for limits to the spatial resolution for the EEG. These are estimated to be around 2 cm

Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.

BACKGROUND For patients with newly diagnosed rheumatoid arthritis, treatment aim is early, rapid, and sustained remission. We compared the efficacy and safety of strategies initiating the interleukin-6 receptor-blocking monoclonal antibody tocilizumab with or without methotrexate (a conventional synthetic disease-modifying antirheumatic drug [DMARD]), versus initiation of methotrexate monotherapy in line with international guidelines. METHODS We did a 2-year, multicentre, randomised, double-blind, double-dummy, strategy study at 21 rheumatology outpatient departments in the Netherlands. We included patients who had been diagnosed with rheumatoid arthritis within 1 year before inclusion, were DMARD-naive, aged 18 years or older, met current rheumatoid arthritis classification criteria, and had a disease activity score assessing 28 joints (DAS28) of at least 2·6. We randomly assigned patients (1:1:1) to start tocilizumab plus methotrexate (the tocilizumab plus methotrexate arm), or tocilizumab plus placebo-methotrexate (the tocilizumab arm), or methotrexate plus placebo-tocilizumab (the methotrexate arm). Tocilizumab was given at 8 mg/kg intravenously every 4 weeks with a maximum of 800 mg per dose. Methotrexate was started at 10 mg per week orally and increased stepwise every 4 weeks by 5 mg to a maximum of 30 mg per week, until remission or dose-limiting toxicity. We did the randomisation using an interactive web response system. Masking was achieved with placebos that were similar in appearance to the active drug; the study physicians, pharmacists, monitors, and patients remained masked during the study, and all assessments were done by masked assessors. Patients not achieving remission on their initial regimen switched from placebo to active treatments; patients in the tocilizumab plus methotrexate arm switched to standard of care therapy (typically methotrexate combined with a tumour necrosis factor inhibitor). When sustained remission was achieved, methotrexate (and placebo-methotrexate) was tapered and stopped, then tocilizumab (and placebo-tocilizumab) was also tapered and stopped. The primary endpoint was the proportion of patients achieving sustained remission (defined as DAS28 <2·6 with a swollen joint count ≤four, persisting for at least 24 weeks) on the initial regimen and during the entire study duration, compared between groups with a two-sided Cochran-Mantel-Haenszel test. Analysis was based on an intention-to-treat method. This trial was registered at ClinicalTrials.gov, number NCT01034137. FINDINGS Between Jan 13, 2010, and July 30, 2012, we recruited and assigned 317 eligible patients to treatment (106 to the tocilizumab plus methotrexate arm, 103 to the tocilizumab arm, and 108 to the methotrexate arm). The study was completed by a similar proportion of patients in the three groups (range 72-78%). The most frequent reasons for dropout were adverse events or intercurrent illness: 27 (34%) of dropouts, and insufficient response: 26 (33%) of dropouts. 91 (86%) of 106 patients in the tocilizumab plus methotrexate arm achieved sustained remission on the initial regimen, compared with 86 (84%) of 103 in the tocilizumab arm, and 48 (44%) of 108 in the methotrexate arm (relative risk [RR] 2·00, 95% CI 1·59-2·51 for tocilizumab plus methotrexate vs methotrexate, and 1·86, 1·48-2·32 for tocilizumab vs methotrexate, p<0·0001 for both comparisons). For the entire study, 91 (86%) of 106 patients in the tocilizumab plus methotrexate arm, 91 (88%) of 103 in the tocilizumab arm, and 83 (77%) of 108 in the methotrexate arm achieved sustained remission (RR 1·13, 95% CI 1·00-1·29, p=0·06 for tocilizumab plus methotrexate vs methotrexate, 1·14, 1·01-1·29, p=0·0356 for tocilizumab vs methotrexate, and p=0·59 for tocilizumab plus methotrexate vs tocilizumab). Nasopharyngitis was the most common adverse event in all three treatment groups, occurring in 38 (36%) of 106 patients in the tocilizumab plus methotrexate arm, 40 (39%) of 103 in the tocilizumab arm, and 37 (34%) of 108 in the methotrexate arm. The occurrence of serious adverse events did not differ between the treatment groups (17 [16%] of 106 patients in the tocilizumab plus methotrexate arm vs 19 [18%] of 103 in the tocilizumab arm and 13 [12%] of 108 in the methotrexate arm), and no deaths occurred during the study. INTERPRETATION For patients with newly diagnosed rheumatoid arthritis, strategies aimed at sustained remission by immediate initiation of tocilizumab with or without methotrexate are more effective, and with a similar safety profile, compared with initiation of methotrexate in line with current standards. FUNDING Roche Nederland BV

Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early) : a multicentre, randomised, double-blind, double-dummy, strategy trial

FINDINGS: Between Jan 13, 2010, and July 30, 2012, we recruited and assigned 317 eligible patients to treatment (106 to the tocilizumab plus methotrexate arm, 103 to the tocilizumab arm, and 108 to the methotrexate arm). The study was completed by a similar proportion of patients in the three groups (range 72-78%). The most frequent reasons for dropout were adverse events or intercurrent illness: 27 (34%) of dropouts, and insufficient response: 26 (33%) of dropouts. 91 (86%) of 106 patients in the tocilizumab plus methotrexate arm achieved sustained remission on the initial regimen, compared with 86 (84%) of 103 in the tocilizumab arm, and 48 (44%) of 108 in the methotrexate arm (relative risk [RR] 2·00, 95% CI 1·59-2·51 for tocilizumab plus methotrexate vs methotrexate, and 1·86, 1·48-2·32 for tocilizumab vs methotrexate, p INTERPRETATION: For patients with newly diagnosed rheumatoid arthritis, strategies aimed at sustained remission by immediate initiation of tocilizumab with or without methotrexate are more effective, and with a similar safety profile, compared with initiation of methotrexate in line with current standards. FUNDING: Roche Nederland BV. BACKGROUND: For patients with newly diagnosed rheumatoid arthritis, treatment aim is early, rapid, and sustained remission. We compared the efficacy and safety of strategies initiating the interleukin-6 receptor-blocking monoclonal antibody tocilizumab with or without methotrexate (a conventional synthetic disease-modifying antirheumatic drug [DMARD]), versus initiation of methotrexate monotherapy in line with international guidelines. METHODS: We did a 2-year, multicentre, randomised, double-blind, double-dummy, strategy study at 21 rheumatology outpatient departments in the Netherlands. We included patients who had been diagnosed with rheumatoid arthritis within 1 year before inclusion, were DMARD-naive, aged 18 years or older, met current rheumatoid arthritis classification criteria, and had a disease activity score assessing 28 joints (DAS28) of at least 2·6. We randomly assigned patients (1:1:1) to start tocilizumab plus methotrexate (the tocilizumab plus methotrexate arm), or tocilizumab plus placebo-methotrexate (the tocilizumab arm), or methotrexate plus placebo-tocilizumab (the methotrexate arm). Tocilizumab was given at 8 mg/kg intravenously every 4 weeks with a maximum of 800 mg per dose. Methotrexate was started at 10 mg per week orally and increased stepwise every 4 weeks by 5 mg to a maximum of 30 mg per week, until remission or dose-limiting toxicity. We did the randomisation using an interactive web response system. Masking was achieved with placebos that were similar in appearance to the active drug; the study physicians, pharmacists, monitors, and patients remained masked during the study, and all assessments were done by masked assessors. Patients not achieving remission on their initial regimen switched from placebo to active treatments; patients in the tocilizumab plus methotrexate arm switched to standard of care therapy (typically methotrexate combined with a tumour necrosis factor inhibitor). When sustained remission was achieved, methotrexate (and placebo-methotrexate) was tapered and stopped, then tocilizumab (and placebo-tocilizumab) was also tapered and stopped. The primary endpoint was the proportion of patients achieving sustained remission (defined as DAS2